{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","groups":[{"description":"Phase I Dose Level 1 Mithramycin 60 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses..","id":"OG000","title":"Phase I Dose Level 1 Mithramycin 60 mcg/kg"},{"description":"Phase I Dose Level -1 Mithramycin 60 mcg/kg followed by Mithramycin 30 mcg/kg\n\nMithramycin: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses.","id":"OG001","title":"Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant in the first group only received one dose, thus was not evaluable.","reportingStatus":"POSTED","timeFrame":"every 8 weeks until at disease progression, approximately 3.5 months","title":"Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR)","type":"PRIMARY","unitOfMeasure":"Participants"}